Rybelsus Now OK'd in First Line; Menopause Before Transition; Novel T2D Drug Flops
(MedPage Today) -- Oral semaglutide (Rybelsus) received an expanded label to include first-line treatment for adults with type 2 diabetes as an adjunct to diet and exercise, Novo Nordisk announced.
The Obesity Society and Obesity Action Coalition...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news
More News: Diabetes | Diabetes Type 2 | Diets | Eating Disorders & Weight Management | Endocrinology | Men | Menopause | Nutrition | Obesity | Sports Medicine